🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Phase II Trial of LM103 in Advanced Melanoma
NCT07310784Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2
92
Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Changchun
2025-12-16
Recruiting
Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
NCT07260708Advanced Cancers
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
42
Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Dalian, Jinan
2025-12-16
Recruiting
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
NCT07311772Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis
Sun Yat-sen University
Phase 3
386
Beijing, Fuzhou, Guangzhou, Shantou, Zhuhai, Nanning, Wuzhou, Changsha
2025-12-16
Recruiting
A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
NCT07323173Systemic Lupus Erythematosus
Nanjing Leads Biolabs Co.,Ltd
Phase 1
117
Bengbu, Beijing, Guangzhou, Changsha, Nanjing, Pingxiang, Shanghai, Taiyuan
2025-12-16
By invitation
Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase
NCT07383298Chronic Myeloid Leukemia
Qian Jiang
Observational
100
Beijing
2025-12-16
Active, closed
the Exploration of MTAP Deletion in Osteosarcoma by Immunohistochemistry
NCT07593573Osteosarcoma, MTAP Deletion, Immunohistochemistry
Peking University People's Hospital
Observational
100
Beijing
2025-12-15
Recruiting
A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
NCT07215494Light Chain (AL) Amyloidosis, MRD
Peking University First Hospital
Not applicable
50
Beijing
2025-12-15
Recruiting
The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster
NCT07307170Herpes Zoster, Mirogabalin, Pain
Beijing Tiantan Hospital
Not applicable
750
Beijing
2025-12-15
Recruiting
The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster
NCT07378046Herpes Zoster, Pain
Beijing Tiantan Hospital
Not applicable
750
Beijing
2025-12-15
Not yet open
CLEAR Trial: CA330 Cytokine Adsorption Column for Anticoagulant/Antiplatelet Patients in Non-Elective CPB Surgery.
NCT07284199CABG, Aortic Dissection, Valvular Heart Diseases
Beijing Anzhen Hospital
Not applicable
120
Beijing
2025-12-15
Recruiting
The Analgesic Efficacy and Safety of Crisugabalin in Patients With Herpes Zoster
NCT07307976Herpes Zoster, Pain
Beijing Tiantan Hospital
Not applicable
750
Beijing
2025-12-15
Recruiting
Lidocaine for LESS Postoperative Shoulder Pain Alleviation
NCT07537127Cystectomy, Myomectomy
Peking Union Medical College Hospital
Not applicable
100
Beijing
2025-12-15
Recruiting
A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
NCT07444307Systemic Lupus Erythematosus (SLE)
Hangzhou Qihan Biotech Co., Ltd.
Phase 1
18
Hefei, Wuhan, Beijing
2025-12-15
Recruiting
The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster
NCT07361796Herpes Zoster, Pain, Postherpetic Neuralgia
Beijing Tiantan Hospital
Not applicable
832
Beijing
2025-12-15
Recruiting
The Analgesic Efficacy and Safety of Loxoprofen Sodium Patch in Patients With Herpes Zoster
NCT07378059Herpes Zoster, Pain
Beijing Tiantan Hospital
Not applicable
750
Beijing
2025-12-15
Recruiting
Humanistic Continuing Care Via WeChat for Patients Undergoing Thermal Ablation of Papillary Thyroid Carcinoma
NCT07302672Papillary Thyroid Carcinoma
Ming-an Yu
Not applicable
108
Beijing
2025-12-15
Recruiting
The Analgesic Efficacy and Safety of Desvenlafaxine in Patients With Herpes Zoster
NCT07361809Herpes Zoster, Pain
Beijing Tiantan Hospital
Not applicable
750
Beijing
2025-12-15
Recruiting
The Analgesic Efficacy and Safety of Tulodesvenlafaxine in Patients With Herpes Zoster
NCT07370389Herpes Zoster, Pain
Beijing Tiantan Hospital
Not applicable
750
Beijing
2025-12-15
Recruiting
The Analgesic Efficacy and Safety of Flurbiprofen Patch in Patients With Herpes Zoster
NCT07370402Herpes Zoster, Pain
Beijing Tiantan Hospital
Not applicable
750
Beijing
2025-12-15
Not yet open
Host-Microbe Interactions in Biliary Dilatation
NCT07152496Choledochal Cyst
Beijing Tsinghua Chang Gung Hospital
Observational
400
Beijing
2025-12-15
Recruiting
Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)
NCT07262645Alzheimer s Disease
Danyang Huichuang Medical Equipment Co., Ltd.
Phase 3
320
Beijing, Shijiazhuang, Baotou, Suzhou, Xi'an, Shanghai, Taiyuan, Tianjin
2025-12-15
Recruiting
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
NCT07276581Rheumatoid Arthritis
AstraZeneca
Phase 2
320
Beijing, Changchun, Changsha, Guangzhou, Jiujiang, Kunming, Linyi, Nanchong
2025-12-15
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
Eli Lilly and Company
Phase 3
1,035
Beijing, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang
2025-12-15
Active, closed
A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular Dystrophy
NCT07282652Duchenne Muscular Dystrophy (DMD)
Peking Union Medical College Hospital
Phase EARLY_PHASE1
12
Beijing
2025-12-12
Recruiting
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
NCT07481058Esophageal Squamous Cell Carcinoma (ESCC)
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2
60
Beijing
2025-12-12
Recruiting
Non-invasive Ultrasound and Hematoma Clearance After Intracerebral Hemorrhage
NCT07246473Intracerebral Hemorrhage
Beijing Tiantan Hospital
Not applicable
86
Wuhu, Beijing
2025-12-12
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
450
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-12-12
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT07222267Breast Cancer, Advanced Solid Tumor
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Nanjing, Shanghai, Tianjin
2025-12-11
Active, closed
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
NCT07223723Amyotrophic Lateral Sclerosis
Biogen
Phase 4
12
Beijing
2025-12-11
Recruiting
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
NCT07326215Acute Respiratory Distress Syndrome, Acute Kidney Injury
Vantive Health LLC
Not applicable
99
Beijing, Guangzhou, Shenzhen, Harbin, Nanjing, Nanchang, Shanghai, Chengdu
2025-12-11
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
Pfizer
Phase 3
800
Hefei, Beijing, Chongqing, Guangzhou, Meizhou, Nanning, Wuhan, Changsha
2025-12-11
Recruiting
AI Facial Analysis Algorithm to Screening Coronary Artery Disease in High-Risk Community Population
NCT07277686Coronary Artery Disease (CAD), Artificial Intelligence Algorithms, Face, Screening
China National Center for Cardiovascular Diseases
Observational
1,392
Zhoukou, Beijing
2025-12-11
Recruiting
A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
NCT07302360Colitis, Ulcerative
Xian-Janssen Pharmaceutical Ltd.
Observational
200
Beijing, Changzhou, Guangzhou, Hangzhou, Nanjing, Shijiazhuang, Tianjin
2025-12-11
Recruiting
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
NCT07226349Advanced Solid Tumor
BeOne Medicines
Phase 1
105
Beijing, Guangzhou, Harbin, Wuhan, Nanjing, Jinan, Weifang
2025-12-11
Recruiting
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .
NCT07242300Upper Limb Spasticity (ULS)
JHM BioPharma (Tonghua) Co. , Ltd.
Phase 3
207
Beijing, Shijiazhuang, Luoyang, Zhengzhou, Changsha, Huai'an, Suzhou, Pingxiang
2025-12-11
Not yet open
A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia
NCT07297875Achondroplasia
Abbisko Therapeutics Co, Ltd
Phase 1/2
110
Beijing, Zhengzhou, Wuhan, Shanghai, Chengde, Chengdu, Hangzhou
2025-12-10
Recruiting
A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography
NCT07230847Coronary Heart Disease, Acute Coronary Syndrome
China National Center for Cardiovascular Diseases
Not applicable
60
Beijing
2025-12-10
Recruiting
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)
NCT07265570Ulcerative Colitis
InSilico Medicine Hong Kong Limited
Phase 2
80
Beijing, Chongqing, Guangzhou, Huizhou, Nanning, Shijiazhuang, Luoyang, Xinxiang
2025-12-10
Not yet open
Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
NCT07277452Pancreatic Cancer, Adult
The First Affiliated Hospital with Nanjing Medical University
Phase 2
156
Nanjing, Beijing
2025-12-10
Not yet open
Gait and Paraspinal sEMG in Degenerative Spinal Diseases
NCT07309926Adult Spinal Deformity, Degenerative Scoliosis, Sagittal Deformity, Sagittal Imbalance
Xuanwu Hospital, Beijing
Observational
120
Beijing
2025-12-10
Not yet open
Songling Xuemaikang Capsules for Cerebral Small Vessel Disease
NCT07271732Hypertension, Cerebral Small Vessel Diseases
Dongzhimen Hospital, Beijing
Not applicable
90
Beijing
2025-12-10
By invitation
Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
NCT07386704Pancreatic Cancer Non-resectable
Peking University First Hospital
Phase 2
30
Beijing
2025-12-09
Recruiting
A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders
NCT06904027Urea Cycle Disorders
Tongji Hospital
Observational
40
Beijing, Guangzhou, Wuhan, Shanghai, Hangzhou
2025-12-09
Recruiting
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension
NCT07654140Uncontrolled Hypertension
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 2
252
Beijing
2025-12-09
Recruiting
The Impact of Image-Assisted Colonoscope on Patient Experience, Physician Workload, and Examination Quality
NCT07541924Colorectal Cancer Screening, Colonic Polyps/Colonoscopy/Colorectal Neoplasms, Difficult Colonoscopy, Colonoscopy-Related Discomfort
DONG WU
Not applicable
200
Beijing
2025-12-09
Recruiting
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
NCT07269210Severe Hypertriglyceridemia
Eli Lilly and Company
Phase 2
60
Beijing, Chengdu, Guangzhou, Luoyang, Shanghai, Xuzhou
2025-12-08
Recruiting
A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo
NCT07153666Vitiligo
Peking University Third Hospital
Observational
170
Beijing
2025-12-08
Recruiting
NWRD06 DNA Plasmid for HCC After Curative Resection.
NCT07324304Hepatocellular Carcinoma (HCC)
Newish Technology (Beijing) Co., Ltd.
Phase 2
30
Beijing, Harbin, Hangzhou
2025-12-08
Not yet open
Characterising the Network-Specific Effects of Piriform Cortex Stimulation Via SEEG
NCT07305311Refractory Epilepsy, Neuromodulation
Xuanwu Hospital, Beijing
Not applicable
10
Beijing
2025-12-08
Active, closed
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
NCT07211776Thyroid Eye Disease (TED)
Zai Lab (Shanghai) Co., Ltd.
Phase 3
108
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou
2025-12-05
Recruiting
A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
NCT07173595Relapsed or Refractory Hematologic Malignancies
Qilu Pharmaceutical Co., Ltd.
Phase 1
186
Beijing
2025-12-05
Recruiting
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
NCT07241416Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
206
Beijing
2025-12-05
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
AstraZeneca
Phase 3
1,100
Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2025-12-04
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
Merck Sharp & Dohme LLC
Phase 2
150
Beijing, Xiamen, Guangzhou, Harbin, Wuhan, Changsha, Nanjing, Nanchang
2025-12-04
Recruiting
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802Plaque Psoriasis
Takeda
Phase 3
110
Beijing, Guangzhou, Changsha, Hangzhou, Shanghai
2025-12-04
Recruiting
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
NCT07262567Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 3
320
Beijing
2025-12-04
Recruiting
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
NCT07255404Pancreatic Ductal Adenocarcinoma (PDAC)
BioNTech SE
Phase 2
105
Beijing, Changchun, Chengdu, Dalian, Guangzhou, Hangzhou, Jinan, Kunming
2025-12-04
Recruiting
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT07283835Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.
Phase 2
16
Beijing, Chongqing, Fuzhou, Wuhan, Changsha, Nanjing, Shenyang, Jinan
2025-12-04
Recruiting
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
NCT07371663Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
Beijing Tide Pharmaceutical Co., Ltd
Phase 1/2
266
Beijing, Zhengzhou, Hangzhou
2025-12-03
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC
Phase 3
500
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Hangzhou
2025-12-03
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
GlaxoSmithKline
Phase 3
450
Shijiazhuang, Shanghai, Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2025-12-03
Recruiting
A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT07265284Psoriasis
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 3
104
Beijing
2025-12-03
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
Bristol-Myers Squibb
Phase 3
366
Beijing, Guangzhou, Shenzhen, Handan, Zhengzhou, Changsha, Jinan, Shanghai
2025-12-03
Recruiting
Balloon Guide Catheter Combined With Filter Protection for Carotid Artery Stenting
NCT07247864Carotid Artery Stenosis
Beijing Anzhen Hospital
Not applicable
296
Beijing
2025-12-03
Recruiting
A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)
NCT07487727Anemia Due to Chronic Kidney Disease
Kind Pharmaceuticals LLC
Phase 3
240
Beijing
2025-12-03
Recruiting
PTC-Guided Therapy for Peritoneal Mesothelioma
NCT07330271Peritoneal Mesothelioma
Beijing Tsinghua Chang Gung Hospital
Not applicable
347
Beijing
2025-12-02
Recruiting
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
NCT06807281Atopic Dermatitis
Pfizer
Phase 3
500
Beijing, Shenzhen, Changsha, Nanchang, Hangzhou, Shanghai
2025-12-02
Recruiting
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
NCT07238283First-line Treatment of Metastatic Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
662
Beijing
2025-12-02
Active, closed
A Study of DII235 in Adults With Elevated Lipoprotein(a)
NCT07235046Lipoprotein Disorder
Novartis Pharmaceuticals
Phase 2
234
Luoyang, Shenyang, Wenzhou, Beijing
2025-12-02
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
Bristol-Myers Squibb
Phase 3
650
Beijing, Haidian District, Guangzhou, Shenzhen, Changsha, Nanjing, Tianjin, Hangzhou
2025-12-02
Not yet open
For Patients With Myocardial Infarction and Multiple Vessel: Testing if Ultrasound (UFR) Can Guide All Needed Treatment in One Procedure, Avoiding a Return Hospital Visit for a Second Operation.
NCT07264881Microvascular Obstruction (MVO), Multivessel Coronary Artery Disease, ACS (Acute Coronary Syndrome), ST Elevation Myocardial Infarction (STEMI)
Beijing Anzhen Hospital
Observational
200
Beijing
2025-12-02
Recruiting
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
NCT07165951Metastatic Pancreatic Ductal Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
566
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-12-02
Recruiting
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
NCT07116031Chronic Graft Versus Host Disease
Sanofi
Phase 2
37
Beijing, Shanghai, Shenzhen, Suzhou
2025-12-02
Recruiting
A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
NCT07042802Ovarian Cancer
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
180
Beijing, Fuzhou, Guangzhou, Harbin, Anyang, Zhengzhou, Xuzhou, Shenyang
2025-12-02
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
AstraZeneca
Phase 1
48
Beijing, Chengdu, Nanjing
2025-12-02
Recruiting
Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
NCT07392346Gastric Cancer Adenocarcinoma Metastatic
Dai, Guanghai
Phase 2
68
Beijing
2025-12-01
Recruiting
Multicenter Randomized Controlled Trial (RCT) and Efficacy Evaluation System Study on Surgical Innovation Strategies for Neonatal Complex Congenital Heart Disease
NCT07363538Complex Congenital Heart Disease
Central China Fuwai Hospital of Zhengzhou University
Not applicable
738
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Qingdao
2025-12-01
Active, closed
Neuromuscular Rehab for ACL Reconstruction: Knee Function & Brain Plasticity
NCT07243860Anterior Cruciate Ligament Injuries
Peking University Third Hospital
Not applicable
50
Beijing
2025-12-01
Recruiting
Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Knee Osteoarthritis(OA)
NCT07347028Myofascial Trigger Points, Migraine, Cervicogenic Headache, Chronic Musculoskeletal Pain
Beijing Tiantan Hospital
Not applicable
1,036
Beijing
2025-12-01
Recruiting
Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Hip Osteoarthritis(OA)
NCT07347041Myofascial Trigger Points, Chronic Musculoskeletal Pain, Hip Osteoarthritis
Beijing Tiantan Hospital
Not applicable
1,036
Beijing
2025-12-01
Recruiting
Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Shoulder Osteoarthritis(OA)
NCT07347054Myofascial Trigger Points, Chronic Musculoskeletal Pain, Shoulder Osteoarthritis
Beijing Tiantan Hospital
Not applicable
1,036
Beijing
2025-12-01
Recruiting
Individualized Application of Anti-Thymocyte Globulin(ATG)in Unrelated Donor Hematopoietic Stem Cell Transplantation
NCT07648992Hematopoietic Stem Cell Transplantation
Daihong Liu
Phase 4
324
Beijing
2025-12-01
Recruiting
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
NCT06514508Multiple Myeloma
Guangzhou Gloria Biosciences Co., Ltd.
Phase 3
60
Beijing, Harbin
2025-12-01
Not yet open
Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors
NCT07275853Advanced Solid Tumors
TCRx Therapeutics Co.Ltd
Phase 1
30
Beijing
2025-12-01
Recruiting
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
NCT07282353Primary Biliary Cholangitis
Cascade Pharmaceuticals, Inc
Phase 3
135
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhanjiang, Nanning
2025-12-01
Recruiting
Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Migraine
NCT07347067Myofascial Trigger Points, Chronic Migraine Headache, Greater Occipital Nerve Block
Beijing Tiantan Hospital
Not applicable
1,036
Beijing
2025-12-01
Recruiting
MPR for Stroke Risk Assessment of ICAS
NCT07309718ICAS - Intracranial Atherosclerosis, Stroke Ischemic, Hemodynamic
Xuanwu Hospital, Beijing
Observational
400
Beijing
2025-12-01
Not yet open
A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
NCT07169175Amyotrophic Lateral Sclerosis (ALS)
SineuGene Therapeutics Co., Ltd.
Phase 1/2
21
Beijing, Fuzhou, Hangzhou
2025-12-01
Active, closed
AI Chatbots for Anxiety Mental Health Literacy
NCT07316374Anxiety Literacy, Anxiety Disorders, Mental Health Literacy
Peking University
Not applicable
200
Beijing
2025-12-01
Not yet open
Evaluating the Safety and Effectiveness of a Vascular Interventional Robotic System in Assisting With Percutaneous Coronary Intervention Procedures: A Prospective, Multicenter, Randomized Controlled Clinical Trial
NCT07233317Coronary Artery Disease
China National Center for Cardiovascular Diseases
Not applicable
170
Beijing
2025-12-01
Recruiting
Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia
NCT07297173Relapsed Leukemia, Refractory Leukemia
Beijing 302 Hospital
Phase 1
5
Beijing
2025-12-01
Recruiting
Diagnostic Value of 68Ga-Pentixafor PET/CT in Adrenal Tumors With Aldosterone and Cortisol Cosecretion
NCT07605156Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion
Peking University First Hospital
Observational
130
Beijing
2025-12-01
Not yet open
A RCT of Moist Ag Dressing in Chronic Wound
NCT07235254Chronic Wound, Hard to Heal Wounds, Dressing, Wound he'a'Ling
Peking University Third Hospital
Not applicable
40
Beijing
2025-12-01
Recruiting
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
NCT07246564Myasthenia Gravis
UCB Biopharma SRL
Phase 4
40
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Jinan, Shanghai, Shenzhen
2025-12-01
Active, closed
Digital Angiography-Derived Fractional Flow Assessment for Intracranial Stenosis
NCT07309705Intracranial Atherosclerosis ICAS, Hemodynamic, Stroke
Xuanwu Hospital, Beijing
Observational
400
Beijing
2025-12-01
Not yet open
A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
NCT07200947SMARCA4-Deficient Tumor, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Zhijie Wang
Phase 2
28
Beijing
2025-12-01
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Eli Lilly and Company
Phase 3
7,140
Beijing, Changchun, Changde, Changzhou, Chengdu, Chongqing, Dalian, Guangzhou
2025-12-01
Recruiting
Intelligent Management Platform for Guiding Exercise Rehabilitation in Coronary Heart Disease Patients
NCT07259278Secondary Prevention of Coronary Heart Disease
China National Center for Cardiovascular Diseases
Not applicable
200
Beijing
2025-12-01
Recruiting
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
NCT07235384Atopic Dermatitis (AD)
Zai Lab (Shanghai) Co., Ltd.
Phase 1
84
Beijing, Jinan, Shanghai, Hangzhou
2025-12-01
Recruiting
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
NCT07182682Non-Small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Phase 3
360
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-12-01
Rows per page Showing 1301–1400 of 5484
Previous 12 13 14 15 16 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=14

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.